• 1
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. 2): II3742.
  • 2
    Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998; 114: 58295.
  • 3
    Jones R, Lydeard S. Dyspepsia in the community: a follow-up study. Br J Clin Pract 1992; 46: 957.
  • 4
    Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 156980.
  • 5
    Agreus L. Socio-economic factors, health care consumption and rating of abdominal symptom severity. A report from the abdominal symptom study. Fam Pract 1993; 10: 15263.
  • 6
    Holtmann G, Goebell H, Talley NJ. Dyspepsia in consulters and non-consulters: prevalence, health-care seeking behaviour, and risk factors. Eur J Gastroenterol Hepatol 1994; 6: 91724.
  • 7
    Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl 1991; 182: 1724.
  • 8
    Marsland DW, Wood M, Mayo F. Content of family practice. Part I. Rank order of diagnoses by frequency. Part II. Diagnoses by disease category and age/sex distribution. J Fam Pract 1976; 3: 3768.
  • 9
    Tougas G, Chen Y, Hwang P, Liu MM, Eggleston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study (Domestic/International Gastroenterology Surveillance Study). Am J Gastroenterol 1999; 94: 284554.
    Direct Link:
  • 10
    Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomized controlled trial. Leeds HELP Study Group. Lancet 2000; 355: 16659.
  • 11
    Peura DA, Gudmundson J, Siepman N, Pilmer BL, Collis CM, Freston J. PPIs: First line treatment for dyspepsia. Am J Gastroenterol 2001; 96: S65(Abstract 204).
  • 12
    Moayyedi P, Forman D, Braunholtz D, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group. Am J Gastroenterol 2000; 95: 144855.
    Direct Link:
  • 13
    Talley NJ, Axon A, Bytzer P, Holtmann G, Lam SK, Van Zanten S. Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999; 13: 113548.
  • 14
    American Gastroenterological Association. Medical position statement: evaluation of dyspepsia. Gastroenterology 1998; 114: 57981.
  • 15
    Malfertheiner P, Megraud F, O'Morain C, et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection—the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 16780.
  • 16
    Delaney BC, Innes MA, Deeks J, et al. Initial management strategies for dyspepsia (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2002.
  • 17
    Moayyedi P, Mason J, Forman D, Drummond MF, Axon AT. Knowledge of negative 13C-urea breath test reduces health care utilization for dyspepsia in a population H. pylori test and treat program. Gastroenterology 2000; 118: A678(Abstract).
  • 18
    Ladabaum U, Chey WD, Scheiman J, Fendrick M. Empiric therapy may be cost-effective compared to H. pylori testing and treatment in some populations with uninvestigated dyspepsia. Aliment Pharmacol Ther 2002; 16: 1491501.
  • 19
    Spiegel BMR, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 127085.
  • 20
    Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia: a meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 3619.
  • 21
    Schilling D, Messerer P, Ott MG, Schauwecker P, Zober A, Riemann JF. Dyspepsia and Helicobacter pylori infection in employees of a large industry. Results of a prospective BASF Helicobacter pylori prevention campaign. Med Klin 2002; 97: 611.
  • 22
    Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 110611.
  • 23
    Veldhuyzen van Zanten SJ, Talley NJ, Blum AL, Bolling-Sternevald E, Sundin M, Junghard O. Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms? Gut 2002; 50(Suppl. 4): iv2630; discussion iv31–2.
  • 24
    Lassen AT, Btyzer P, Schaffalitzky de Muckadell OB. H. pylori testing or prompt endoscopy for dyspeptic patients in primary care: a randomized controlled trial of two management strategies. Gastroenterology 1997; 112: A24(Abstract).
  • 25
    Loffeld RJ, Van Der Hulst RW. Helicobacter pylori and gastro-oesophageal reflux disease: association and clinical implications. To treat or not to treat with anti-H. pylori therapy? Scand J Gastroenterol Suppl 2002; 236: 1518.
  • 26
    Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 29927.
    Direct Link:
  • 27
    Graham DY. Helicobacter pylori is not and never was ‘protective’ against anything, including GERD. Dig Dis Sci 2003; 48: 62930.
  • 28
    Veldhuyzen van Zanten S, Chiba N, Armstrong D, et al. A double-blind randomized controlled trial comparing omeprazole, ranitidine, cisapride and placebo in 512 Helicobacter pylori (Hp) negative primary care patients with uninvestigated dyspepsia (UD) − the CADET HN study. Am J Gastroenterol 2001; 96(Suppl. 1): S9, S77–S78(Abstract 243).
  • 29
    Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11: 5416.
  • 30
    Chiba N, Veldhuyzen Van Zanten SJ. 13C-Urea breath tests are the noninvasive method of choice for Helicobacter pylori detection. Can J Gastroenterol 1999; 13: 6813.
  • 31
    Chey WD, Fendrick AM. Noninvasive Helicobacter pylori testing for the ‘test-and-treat’ strategy: a decision analysis to assess the effect of past infection on test choice. Arch Intern Med 2001; 161: 212932.
  • 32
    Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16(Suppl. 1): 315.
  • 33
    NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 659.
  • 34
    Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. Br Med J 2000; 321: 65964.
  • 35
    Malfertheiner P, Össner JM, Fischbach W, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharm Ther 2003; 18: 61525.
  • 36
    Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in non-ulcer dyspepsia. Resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 26216.
    Direct Link:
  • 37
    Delaney BC, Wilson S, Roalfe A, et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomized controlled trial in primary care. Lancet 2000; 356: 19659.
  • 38
    Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003; 1: CD001960.
  • 39
    Peura DA, Kovacs TO, Metz D, Gudmundson JL, Pilmer BL. Low-dose lansoprazole: Effective for non-ulcer dyspepsia (NUD). Gastroenterology 2000; 118: A439(Abstract).
  • 40
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 3345: 7849.